Stock Detail
ATHERSYS INC
Biotechnology
ATHX @ Yahoo Finance | ATHX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.28 | $1.29 | $-0.02 | -1.54% | 0.00 | $1.30 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.28 | $1.25 | 38,895 | 30.08M | 50,965.5 | -2.46 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.31 | 1.29 | 1.27 | 1.25 | 1.23 |
Stock Profile
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes ATHX-105, a Phase I clinical trial product for the treatment of obesity. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders that include sleep disorders, such as narcolepsy or excessive daytime sleepiness; and other potential indications, such as attention deficit hyperactivity disorder and other cognitive disorders. In addition, Athersys, through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for bone marrow transplant/oncology support, ischemic stroke, and other disease indications. Athersys is based in Cleveland, Ohio.